"Agent" means any third party that collects or uses personal information under the instructions of, and solely for, the Companies or to which the Companies disclose personal information for use on their behalf.
"Amersham Biosciences" means Amersham Biosciences Corp, Amersham Biosciences (SV) Corp, AG Technology Inc., InnovaSep Technology Corp, and Praelux, Inc. dba Amersham Biosciences in the United States, as well as Cimarron Inc.
"Amersham Health" means Amersham Health Inc. and Medi-Physics, Inc. dba Amersham Health in the United States.
"Personal information" means any information or set of information that identifies or is used by or on behalf of the Companies to identify an individual. Personal information does not include information that is encoded or anonymized, or publicly available information that has not been combined with non-public personal information.
"Sensitive personal information" means personal information that reveals race, ethnic origin, sexual orientation, political opinions, religious or philosophical beliefs, or trade union membership, or that concerns an individual's health. In addition, the Companies will treat as sensitive personal information any information received from a third party where that third party treats and identifies the information as sensitive.
"The Companies" means Amersham Biosciences, Amersham Health and their respective successors, subsidiaries, divisions and groups in the United States.
NOTICE: Where the Companies collect personal information directly from individuals in the EU, it will inform them about the type of personal information collected, the purposes for which it collects and uses the personal information, and the types of non-agent third parties to which the Companies disclose or may disclose that information, and the choices and means, if any, the Companies offer individuals for limiting the use and disclosure of their personal information. Notice will be provided in clear and conspicuous language when individuals are first asked to provide personal information to the Companies, or as soon as practicable thereafter, and in any event before the Companies use or disclose the information for a purpose other than that for which it was originally collected.
Where the Companies receive personal information from their subsidiaries, affiliates or other entities in the EU, they will use and disclose such information in accordance with the notices provided by such entities and the choices made by the individuals to whom such personal information relates.
CHOICE: The Companies will offer individuals the opportunity to choose (opt-out) whether their personal information is (a) to be disclosed to a non-agent third party, or (b) to be used for a purpose other than the purpose for which it was originally collected or subsequently authorized by the individual.
For sensitive personal information, the Companies will give individuals the opportunity to affirmatively and explicitly (opt-in) consent to the disclosure of the information to a non-agent third party or the use of the information for a purpose other than the purpose for which it was originally collected or subsequently authorized by the individual.
The Companies will provide individuals with reasonable mechanisms to exercise their choices.
DATA INTEGRITY: The Companies will use personal information only in ways that are compatible with the purposes for which it was collected or subsequently authorized by the individual. The Companies will take reasonable steps to ensure that personal information is relevant to its intended use, accurate, complete, and current.
TRANSFERS TO AGENTS: The Companies will obtain assurances from their agents that they will safeguard personal information consistently with this Policy. Examples of appropriate assurances that may be provided by agents include: a contract obligating the agent to provide at least the same level of protection as is required by the relevant Safe Harbor Principles, being subject to EU Directive 95/46/EC (the EU Data Protection Directive), Safe Harbor certification by the agent, or being subject to another European Commission adequacy finding. Where the Companies become aware that an agent is using or disclosing personal information in a manner contrary to this Policy, the Companies will take reasonable steps to prevent or stop the use or disclosure.
ACCESS AND CORRECTION: Upon request, the Companies will grant individuals reasonable access to personal information that it holds about them. In addition, the Companies will take reasonable steps to permit individuals to correct, amend, or delete information that is demonstrated to be inaccurate or incomplete.
SECURITY: The Companies will take reasonable precautions to protect personal information in its possession from loss, misuse and unauthorized access, disclosure, alteration and destruction.
ENFORCEMENT: The Companies will conduct compliance audits of its relevant privacy practices to verify adherence to this Policy. Any employee that the Companies determine is in violation of this policy will be subject to disciplinary action up to and including termination of employment.
DISPUTE RESOLUTION: Any questions or concerns regarding the use or disclosure of personal information should be directed to the Companies' Privacy Office at the address given below. The Companies will investigate and attempt to resolve complaints and disputes regarding use and disclosure of personal information in accordance with the principles contained in this Policy. For complaints that cannot be resolved between the Companies and the complainant, the Companies have agreed to participate in the dispute resolution procedures of the panel established by the European data protection authorities to resolve disputes pursuant to the Safe Harbor Principles.
LIMITATION ON APPLICATION OF PRINCIPLES
GE Healthcare Life Sciences
EFFECTIVE DATE: April 11, 2003